Guan-Qun Zhou
Overview
Explore the profile of Guan-Qun Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
3279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang Y, Liu X, Shen L, Hu G, Zou G, Zhang N, et al.
JAMA
. 2025 Mar;
PMID: 40079940
Importance: Approximately 20% to 30% of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) experience disease relapse despite definitive chemoradiotherapy. The programmed cell death 1 (PD-1) blockade camrelizumab has demonstrated considerable...
2.
Xu C, Zhou G, Li W, Hu D, Chen X, Lin S, et al.
Cancer Cell
. 2025 Feb;
PMID: 40020668
Severe toxicities caused by concurrent cisplatin are a critical problem in nasopharyngeal carcinoma (NPC) treatment. In this phase 2 multicenter PLATINUM trial (NCT03984357), we recruited 152 NPC patients who received...
3.
Tang L, Chen L, Xu G, Zhang N, Huang C, Li W, et al.
CA Cancer J Clin
. 2025 Feb;
PMID: 39970442
Background: Nearly 90% locoregionally advanced nasopharyngeal carcinoma (LANPC) responds to induction chemotherapy (IC) with significant tumor volume shrinkage. Radiotherapy always follows IC, and reduced volume has been proposed. However, the...
4.
Kou J, Peng J, Lv W, Wu C, Chen Z, Zhou G, et al.
Radiol Artif Intell
. 2025 Jan;
7(2):e230544.
PMID: 39812582
Purpose To develop and evaluate a deep learning-based prognostic model for predicting survival in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) using serial MRI before and after induction chemotherapy (IC). Materials and...
5.
Yang Y, Yang X, Jiang X, Lin L, Wang G, Sun W, et al.
Int J Radiat Oncol Biol Phys
. 2024 Dec;
PMID: 39708045
Purpose: To establish an artificial intelligence (AI)-empowered multistep integrated (MSI) radiation therapy (RT) workflow for patients with nasopharyngeal carcinoma (NPC) and evaluate its feasibility and clinical performance. Methods And Materials:...
6.
Lv J, Xu L, Li Z, Lin L, Wu C, Quan T, et al.
Cancer Cell
. 2024 Jul;
42(8):1401-1414.e4.
PMID: 39059389
Recurrence risks of cancer patient can change during treatment as a result of treatment-related tumor evolution. However, biomarkers that can monitor these changes are lacking. Here, we investigated whether tracking...
7.
Liu X, Zhang Y, Yang K, Zhang N, Jin F, Zou G, et al.
Lancet
. 2024 Jun;
403(10445):2720-2731.
PMID: 38824941
Background: Anti-PD-1 therapy and chemotherapy is a recommended first-line treatment for recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains unknown in patients with locoregionally advanced nasopharyngeal...
8.
Yang Z, Peng Y, Wang Y, Yang P, Huang Z, Quan T, et al.
Oncogene
. 2024 Apr;
43(23):1779-1795.
PMID: 38649438
Transcription factors (TFs) engage in various cellular essential processes including differentiation, growth and migration. However, the master TF involved in distant metastasis of nasopharyngeal carcinoma (NPC) remains largely unclear. Here...
9.
Huang C, Zhang N, Jiang W, Xie F, Pei X, Huang S, et al.
J Clin Oncol
. 2024 Mar;
42(17):2021-2025.
PMID: 38507662
JCO We previously reported comparable 3-year regional relapse-free survival (RRFS) using elective upper-neck irradiation (UNI) in N0-1 nasopharyngeal carcinoma (NPC) compared with standard whole-neck irradiation (WNI). Here, we present the...
10.
Zhang W, Lin J, Wang G, Huang C, Tang L, Mao Y, et al.
Radiother Oncol
. 2024 Mar;
194:110189.
PMID: 38432309
Background And Purpose: Whether concurrent chemoradiotherapy would provide survival benefits in patients with stage II and T3N0 NPC with adverse factors remains unclear in IMRT era. We aimed to assess...